within Pharmacolibrary.Drugs.ATC.N;

model N06BX07_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.002,
    adminDuration  = 600,
    adminMass      = 0.8,
    adminCount     = 1,
    Vd             = 0.00061,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Oxiracetam is a nootropic compound of the racetam family, used primarily as a cognitive enhancer in research settings. It is not approved for clinical use in the United States or most countries, but is used in some regions for cognitive impairment and dementia. Its mechanism of action is not fully understood, but is thought to involve modulation of central cholinergic and glutamatergic systems.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following single intravenous (IV) administration in healthy adults.</p><h4>References</h4><ol><li><p>Perucca, E, et al., &amp; Crema, A (1984). Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers. <i>European journal of drug metabolism and pharmacokinetics</i> 9(3) 267–274. DOI:<a href=&quot;https://doi.org/10.1007/BF03189650&quot;>10.1007/BF03189650</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6519128/&quot;>https://pubmed.ncbi.nlm.nih.gov/6519128</a></p></li><li><p>Liang, D, et al., &amp; Sun, H (2021). Pharmacokinetic Properties of S-oxiracetam After Single and Multiple Intravenous Infusions in Healthy Volunteers. <i>European journal of drug metabolism and pharmacokinetics</i> 46(6) 793–805. DOI:<a href=&quot;https://doi.org/10.1007/s13318-021-00718-9&quot;>10.1007/s13318-021-00718-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34549388/&quot;>https://pubmed.ncbi.nlm.nih.gov/34549388</a></p></li><li><p>Parnetti, L (1995). Clinical pharmacokinetics of drugs for Alzheimer&#x27;s disease. <i>Clinical pharmacokinetics</i> 29(2) 110–129. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199529020-00005&quot;>10.2165/00003088-199529020-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7586900/&quot;>https://pubmed.ncbi.nlm.nih.gov/7586900</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06BX07_1;
